PubRank

Z K Wszolek

Author PubWeight™ 87.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phenotypic correlations in FTDP-17. Neurobiol Aging 2001 3.96
2 DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007 2.86
3 TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2010 1.93
4 Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology 2004 1.87
5 A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 1.86
6 A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998 1.84
7 Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009 1.76
8 A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 1995 1.64
9 Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology 2007 1.62
10 Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 2009 1.48
11 Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl 2006 1.46
12 Novel THAP1 sequence variants in primary dystonia. Neurology 2010 1.42
13 Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry 2006 1.41
14 Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008 1.39
15 Parkinson disease: handedness predicts asymmetry. Neurology 2005 1.37
16 Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013 1.31
17 Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity? Neurology 2009 1.27
18 MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011 1.19
19 Association of the MAPT locus with Parkinson's disease. Eur J Neurol 2009 1.19
20 Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008 1.18
21 Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol 2003 1.18
22 Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Bone Marrow Transplant 1999 1.17
23 Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology 2009 1.16
24 Thalamic deep brain stimulation for essential tremor: recommendations for long-term outcome analysis. Can J Neurol Sci 2004 1.13
25 Characterization of DCTN1 genetic variability in neurodegeneration. Neurology 2009 1.11
26 Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2003 1.08
27 Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids. Neurology 2008 1.07
28 Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Hum Mol Genet 1996 1.07
29 The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration"). J Neuropathol Exp Neurol 1998 1.06
30 Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathol 2008 1.06
31 Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord 2008 1.04
32 Bilateral thalamic deep brain stimulation: midline tremor control. J Neurol Neurosurg Psychiatry 2005 1.03
33 Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology 2011 0.99
34 SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology 2002 0.98
35 Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann Neurol 1999 0.94
36 Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur J Hum Genet 2001 0.93
37 Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. Neurology 2011 0.93
38 MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology. Neurology 2010 0.92
39 Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994 0.92
40 Genetic complexity and Parkinson's disease. Science 1997 0.91
41 Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke. Eur J Neurol 2012 0.91
42 SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol 2010 0.90
43 Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 2011 0.90
44 Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation. Brain 2001 0.90
45 Familial parkinsonism: Our experience and review. Parkinsonism Relat Disord 1995 0.88
46 Thalamic deep brain stimulation for tremor-predominant Parkinson's disease. Parkinsonism Relat Disord 2003 0.88
47 Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation. J Neural Transm (Vienna) 2007 0.88
48 Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology 2011 0.87
49 Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Hum Mol Genet 1998 0.87
50 Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). Neurology 2002 0.87
51 Effects of midazolam on electroencephalograms of seriously ill patients. Mayo Clin Proc 1992 0.86
52 A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology 2011 0.84
53 Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995 0.84
54 MEIS1 p.R272H in familial restless legs syndrome. Neurology 2009 0.84
55 Susceptibility genes for restless legs syndrome are not associated with Parkinson disease. Neurology 2008 0.83
56 Temporal intermittent rhythmic delta activity in electroencephalograms. J Clin Neurophysiol 1995 0.82
57 Familial parkinsonism, dementia, and Lewy body disease: study of family G. Ann Neurol 1997 0.81
58 Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis. J Neural Transm (Vienna) 2006 0.81
59 Japanese family with parkinsonism, depression, weight loss, and central hypoventilation. Neurology 2002 0.81
60 Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation. Parkinsonism Relat Disord 2003 0.81
61 Olfactory dysfunction in familial parkinsonism. Neurology 1997 0.80
62 Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. Parkinsonism Relat Disord 2001 0.80
63 Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol 2015 0.80
64 An independent replication of PARK16 in Asian samples. Neurology 2010 0.80
65 PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 1999 0.79
66 Frontotemporal dementia and parkinsonism linked to chromosome 17--the first Polish family. Eur J Neurol 2011 0.79
67 A novel approach to dementia: high-resolution 1H MRI of the human hippocampus performed at 21.1 T. Neurology 2010 0.78
68 Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family. Neurology 1996 0.78
69 Brain acetylcholinesterase activity in FTDP-17 studied by PET. Neurology 2006 0.78
70 GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease. Eur J Neurol 2009 0.77
71 Interest in genetic testing in pallido-ponto-nigral degeneration (PPND): a family with frontotemporal dementia with Parkinsonism linked to chromosome 17. Eur J Neurol 2001 0.77
72 Medications used to treat Parkinson's disease and the risk of gambling. Eur J Neurol 2008 0.77
73 Recent advances in the understanding of tau protein and movement disorders. Curr Opin Neurol 2001 0.76
74 Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology 2003 0.76
75 New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2006 0.76
76 The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996 0.76
77 Death-associated protein kinase 1 variation and Parkinson's disease. Eur J Neurol 2010 0.76
78 Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. J Neural Transm (Vienna) 2005 0.76
79 Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000 0.75
80 Calbindin-1 association and Parkinson's disease. Eur J Neurol 2009 0.75
81 A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 2000 0.75
82 Cervical dystonia: a review the role of botulinum toxin. Nebr Med J 1995 0.75
83 Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Acta Neurol Scand 1996 0.75
84 Is there a genetic susceptibility to idiopathic parkinsonism? Parkinsonism Relat Disord 1995 0.75
85 Neurocysticercosis: a case report. Nebr Med J 1989 0.75
86 Magnetic resonance imaging in thoracic outlet syndrome. Nebr Med J 1988 0.75
87 Sporadic diffuse leucoencephalopathy with axonal spheroids: report of a profuse and rapid cortical-spinal degeneration. Neurol Sci 2011 0.75
88 Brainstem auditory evoked potentials in liver transplant candidates. Nebr Med J 1995 0.75
89 Benedykt Dybowski--physician, explorer, scientist, political prisoner. Mayo Clin Proc 1990 0.75
90 Thoracic outlet syndrome. Neurosurgery 1988 0.75
91 Simultaneous electromyography and manometry of the anal sphincters in parkinsonian patients: technical considerations. Muscle Nerve 1996 0.75
92 Concerning neuroprotective therapy for Parkinson's disease. J Neural Transm Suppl 2006 0.75
93 Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer 2000 0.75
94 Electroencephalographic abnormalities in liver transplant recipients: practical considerations and review. J Clin Neurophysiol 1996 0.75
95 Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Acta Neurol Scand 1995 0.75
96 Drug-induced parkinsonism after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996 0.75
97 Autosomal-dominant Parkinson's disease linked to 2p13 is not caused by mutations in transforming growth factor alpha (TGF alpha) (short communication). J Neural Transm (Vienna) 2001 0.75
98 Arteriovenous malformation of the brain. Nebr Med J 1987 0.75